Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasm Metastasis 1Multiple Sclerosis, Chronic Progressive 1Multiple Sclerosis 1Multiple Myeloma 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Natalizumab × Clear all
NCT01416181 2017-09-11

ASCEND in SPMS

Biogen

Phase 3 Terminated
889 enrolled 31 charts

Multiple Sclerosis, Neoplasm Metastasis, Multiple Sclerosis, Chronic Progressive

NCT00675428 2014-09-19

Study of Natalizumab in Relapsed/Refractory Multiple Myeloma

Biogen

Phase 1/2 Terminated
6 enrolled 6 charts
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡